An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

Study summary

The phase I/II trial assess the safety and efficacy of a new positron emission tomography (PET) test for early diagnosis of lung cancer. This study uses PET and Me-4FDG new glucose tracer (alpha-methyl-4-deoxy-4-\[(18)F\]fluoro-D-glucopyranoside) designed specifically to determine glucose update into cells in the body. PET is a non-invasive imaging method used to detect cancer in patient. Me4FDG is a radioactive glucose tracer used in PET to locate cells in the body taking up glucose by SGLT2. SLGT2 is a sodium glucose transport protein that accumulates glucose in some cells, e.g. kidney cells and tumors. This study may help researcher determine how effective PET with ME4FDG tracer works in detecting lung cancer.

Ask AI to explain this study

Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedAlpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside and Computed Tomography

Plus 2 other study approaches.

Who it may be forLung Adenocarcinoma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 10, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Jonsson Comprehensive Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Diagnostic
Study type: Interventional
Phase: Phase 1 / Phase 2
Sponsor: Jonsson Comprehensive Cancer Center
Interventions being studied: Drug: Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside; Procedure: Computed Tomography; Other: Laboratory Biomarker Analysis; Procedure: Positron Emission Tomography

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Age \> 18 years
Lung nodule \>= 1 cm visualized by CT imaging
CANCER ARM: Pathologically confirmed lung adenocarcinoma. For patients who are surgical candidates, the pathologic report on the surgical specimen will confirm the diagnosis. For patients who are not surgical candidates, the enrollment will be contingent upon a pathologic diagnosis of lung cancer obtained by needle biopsy
BENIGN ARM: Lung nodules considered to be clinically benign, according to the Guidelines for Management of Incidental Pulmonary Nodules from the Fleischner Society. Will consider "benign" the nodules with a lung-RADS score of 1-3

Reasons someone may not be able to joinExclusion criteria

Pregnancy
Diagnosis of diabetes
Current treatment with SGLT2 inhibitors or metformin

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Yesenia CalzadaLos Angeles, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 10, 2025. Always confirm current availability with the study team.

View original record ↗